Endeavor

Moffitt Cancer Center Leaders Highlight Importance of Cancer Research in D.C.

Ongoing cancer research funding is essential to Moffitt’s mission

Single-Drug Immunotherapy Shows Success in Rare Skin Cancer

Pembrolizumab delivers 89% response rate in desmoplastic melanoma, sparing patients from harsher combination treatments

Moffitt Study Uncovers New Mechanism of Immunotherapy Resistance

Cancer-induced nerve injury weakens anti-PD-1 treatment, but novel approaches may overcome it

Powered by Positivity in the Fight Against Kidney Cancer

Moffitt patient’s outlook combines determination, faith and support

Dendritic Cell Vaccines Changing Landscape for Breast Cancer Treatment

Moffitt research shows promise in breakthrough immunotherapy treatment

Improving Outcomes for Patients With Synovial Sarcoma

Moffitt treats first patient in the world with FDA-approved Tecelra

President Biden’s Diagnosis Spotlights Growing Progress in Prostate Cancer Care

CAR T-cell therapy, bisphosphonates and targeted radiation offer new hope for patients with advanced disease

Is Immunotherapy Before and After Surgery a Better Strategy for Certain Cancers?

Several studies from the ASCO Annual Meeting suggest earlier use of immunotherapy improves survival for colon, head and neck and stomach cancers

Can Triplet Therapy Help Treat Symptomatic Melanoma Brain Metastases?

Targeted therapy combined with immunotherapy gave patients longer progression-free survival and higher response rates, study says